Herceptin Related Published Studies
Well-designed clinical trials related to Herceptin (Trastuzumab)
Safety profile of Pertuzumab with Trastuzumab and Docetaxel in patients from Asia
with human epidermal growth factor receptor 2-positive metastatic breast cancer:
results from the phase III trial CLEOPATRA. [2014]
First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with
trastuzumab and docetaxel for HER2-positive metastatic breast cancer. [2013]
Adjuvant trastuzumab in HER2-positive breast cancer. [2011.10.06]
Surgery following neoadjuvant therapy in patients with HER2-positive locally advanced or inflammatory breast cancer participating in the NeOAdjuvant Herceptin (NOAH) study. [2011.10]
Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. [2011.09.01]
Rationale and design of the Multidisciplinary Approach to Novel Therapies in Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized, placebo-controlled trial to determine if conventional heart failure pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling among patients with HER2+ early breast cancer using cardiac MRI. [2011.07.27]
Evaluation of trastuzumab without chemotherapy as a post-operative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial [RESPECT (N-SAS BC07)]. [2011.05]
Randomized phase II study comparing efficacy and safety of combination-therapy trastuzumab and docetaxel vs. sequential therapy of trastuzumab followed by docetaxel alone at progression as first-line chemotherapy in patients with HER2+ metastatic breast cancer: HERTAX trial. [2011.04]
Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. [2011.03]
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study. [2011.01.20]
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. [2011.01.10]
Rationale and design of the Multidisciplinary Approach to Novel Therapies in
Cardiology Oncology Research Trial (MANTICORE 101--Breast): a randomized,
placebo-controlled trial to determine if conventional heart failure
pharmacotherapy can prevent trastuzumab-mediated left ventricular remodeling
among patients with HER2+ early breast cancer using cardiac MRI. [2011]
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer. [2010.12.01]
Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial. [2010.09]
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. [2010.08.28]
Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. [2010.07.20]
A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients. [2010.07]
Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. [2010.04.20]
First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. [2010.03.20]
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. [2010.03.01]
Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. [2010.02.20]
Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. [2010.01.30]
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. [2010.01]
CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive
metastatic breast cancer. [2010]
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trial. [2009.12.20]
Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial. [2009.12.01]
Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. [2009.11.20]
Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. [2009.06.20]
Radiotherapy and adjuvant trastuzumab in operable breast cancer: tolerability and adverse event data from the NCCTG Phase III Trial N9831. [2009.06.01]
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. [2009.04.20]
A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. [2008.12]
The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. [2008.06]
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. [2008.06]
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. [2008.04.01]
Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. [2007.09.01]
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. [2007.09.01]
The model-based cost-effectiveness analysis of 1-year adjuvant trastuzumab treatment: based on 2-year follow-up HERA trial data. [2007.07.28]
Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab. [2007.05]
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. [2006.06.20]
Variations in the number of regulatory T cells (CD4+CD25+) in patients with breast cancer during herceptin therapy. [2006.03]
Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. [2006.02.23]
Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma. [2005.11.15]
Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. [2005.11.01]
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. [2005.10.20]
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. [2005.10.20]
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. [2005.07.01]
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. [2005.06.01]
A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. [2005.06]
Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer. [2004.10]
Trastuzumab plus docetaxel in HER-2/neu-positive prostate carcinoma: final results from the California Cancer Consortium Screening and Phase II Trial. [2004.05.15]
Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. [2004.01]
Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer. [2002.07.15]
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. [2002.02.01]
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials. [2001.02]
First-line Herceptin monotherapy in metastatic breast cancer. [2001]
Trastuzumab combined with chemotherapy for the treatment of HER2-positive metastatic breast cancer: pivotal trial data. [2001]
Well-designed clinical trials possibly related to Herceptin (Trastuzumab)
Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy. [2011.03.01]
Predictive biomarker validation in practice: lessons from real trials. [2010.10]
Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. [2010.09.15]
Detection and HER2 expression of circulating tumor cells: prospective monitoring in breast cancer patients treated in the neoadjuvant GeparQuattro trial. [2010.05.01]
Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study. [2010.04.20]
Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up. [2010.04]
Single circulating tumor cell detection and overall survival in nonmetastatic breast cancer. [2010.04]
Participants' uptake of clinical trial results: a randomised experiment. [2010.03.30]
Time to full publication of studies of anticancer drugs for breast cancer, and the potential for publication bias. [2010.01]
Lapatinib for the treatment of HER2-overexpressing breast cancer. [2009.10]
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment. [2009.10]
Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges. [2009.08.20]
The impact of sharing results of a randomized breast cancer clinical trial with study participants. [2009.05]
A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancer: a Hellenic Cooperative Oncology Group study. [2009.05]
Lessons learned from independent central review. [2009.01]
Is risk of central nervous system (CNS) relapse related to adjuvant taxane treatment in node-positive breast cancer? Results of the CNS substudy in the intergroup Phase III BIG 02-98 Trial. [2008.11]
Q-TWiST analysis of lapatinib combined with capecitabine for the treatment of metastatic breast cancer. [2008.09.02]
A randomized clinical trial of adjuvant chemotherapy for radically resected locoregional relapse of breast cancer: IBCSG 27-02, BIG 1-02, and NSABP B-37. [2008.06]
Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. [2007.06.01]
Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials. [2007.04.11]
HER2 (erbB-2)-targeted effects of the omega-3 polyunsaturated. Fatty acid alpha-linolenic acid (ALA; 18:3n-3) in breast cancer cells: the <<fat features>> of the <<Mediterranean diet>> as an <<anti-HER2 cocktail>>. [2006.11]
Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. [2004.09.15]
Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer. [2003]
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [2001.03.15]
Fluorescence in situ hybridization (FISH) for detection of HER-2/neu amplification in breast cancer: a multicenter portability study. [2000.01]
c-erbB-2 in serum of patients receiving fractionated paclitaxel chemotherapy. [1999.04]
[Adjuvant systemic therapy of breast cancer--prognostic and predictive factors] [1999]
Other research related to Herceptin (Trastuzumab)
Genomic analysis reveals that immune function genes are strongly linked to
clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant
Trastuzumab Trial. [2015]
Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant
trastuzumab in the NSABP B-31 trial. [2015]
[Trastuzumab administered concurrently with anthracycline-containing adjuvant
regimen for breast cancer]. [Article in Chinese] [2014]
Population pharmacokinetics and exposure-response analyses of trastuzumab in
patients with advanced gastric or gastroesophageal junction cancer. [2014]
Outcome of patients with HER2-positive breast cancer treated with or without
adjuvant trastuzumab in the Finland Capecitabine Trial (FinXX). [2014]
Cost-effectiveness analysis of trastuzumab in the adjuvant treatment for early
breast cancer. [2014]
Skin/nail infections with the addition of pertuzumab to trastuzumab-based
chemotherapy. [2014]
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor
2-positive breast cancer: planned joint analysis of overall survival from NSABP
B-31 and NCCTG N9831. [2014]
Dose-dense sequential adjuvant chemotherapy followed, as indicated, by
trastuzumab for one year in patients with early breast cancer: first report at
5-year median follow-up of a Hellenic Cooperative Oncology Group randomized phase
III trial. [2014]
Quality of life in the trastuzumab for gastric cancer trial. [2014]
A Phase II study of bevacizumab in combination with trastuzumab and docetaxel in
HER2 positive metastatic breast cancer. [2014]
Subcutaneous trastuzumab: a review of its use in HER2-positive breast cancer. [2014]
Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic
review of randomized controlled trials. [2013]
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. [2013]
Fluorouracil, epirubicin, and cyclophosphamide (FEC-75) followed by paclitaxel
plus trastuzumab versus paclitaxel plus trastuzumab followed by FEC-75 plus
trastuzumab as neoadjuvant treatment for patients with HER2-positive breast
cancer (Z1041): a randomised, controlled, phase 3 trial. [2013]
Trastuzumab: a review of its use in HER2-positive advanced gastric cancer. [2013]
Comparative pharmacokinetics of subcutaneous trastuzumab administered via
handheld syringe or proprietary single-use injection device in healthy males. [2013]
Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin)
using hyaluronidase. [2013]
|